STIOLTO RESPIMAT Rx
Generic Name and Formulations:
Tiotropium 2.5mcg, olodaterol 2.5mcg; per actuation; inhalation spray; contains benzalkonium chloride.
Boehringer Ingelheim Pharmaceuticals
Indications for STIOLTO RESPIMAT:
Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Limitations Of use:
Not for treating asthma or acute deteriorations of COPD.
Take at same time each day. 2 inhalations once daily; max 2 inhalations/day.
LABA use in asthma patients without use of long-term control medication.
LABAs may increase risk of asthma-related death. Do not initiate in patients with acutely deteriorating COPD. Not for relief of acute bronchospasm. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Not for use with other long-acting β2-agonists. Discontinue if paradoxical bronchospasm or hypersensitivity reactions occur; use alternative therapy. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertrophic obstructive cardiomyopathy, hypertension). Convulsive disorders. Thyrotoxicosis. Prolongation of the QT interval. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Narrow-angle glaucoma. Monitor for signs/symptoms of prostatic hyperplasia, GI or GU obstruction. Risk of hypokalemia or hyperglycemia. Moderate-to-severe renal impairment: monitor for anticholinergic effects. Severe hepatic impairment. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Anticholinergic + long-acting beta-2 agonist (LABA).
Avoid with other anticholinergics. Caution with concomitant other adrenergic drugs. Concomitant xanthine derivatives, steroids, diuretics may potentiate hypokalemia. Extreme caution with MAOIs, tricyclics, or drugs known to prolong QTc interval. Antagonized by β-blockers; if needed, consider cardioselective agents. Potentiated by strong CYP450 and P-gp inhibitors (eg, ketoconazole).
Nasopharyngitis, cough, back pain; paradoxical bronchospasm, urinary retention, hypokalemia, hypersensitivity reactions.
Inhaler (w. cartridge)—4g (60 inh)
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Population-Based Incidence of Acute Idiopathic Optic Neuritis Estimated
- First-in-Class Therapy Approved for Polyneuropathy Caused by hATTR
- High Anxiety Symptoms Prevalent in Epilepsy, Mesial Temporal Sclerosis
- Advance Care Planning Doesn't Aid Quality of Life
- Variation in Specialty Drug Coverage Across Health Plans